Desjardins Global Asset Management’s United Therapeutics UTHR Stock Holding History

Desjardins Global Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$1.58M	Sell	7,165 -146	-2%	-$33.7K	0.17%	141
2023 Q3	$1.65M	Buy	+7,311	New	+$1.68M	0.18%	133
2023 Q2	–	Sell	-4,718	Closed	-$1.06M	–	650
2023 Q1	$1.06M	Buy	+4,718	New	+$1.16M	0.13%	145

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Desjardins Global Asset Management's UTHR Position: Q4 2023 in Review

Desjardins Global Asset Management reduced its United Therapeutics (UTHR) stake by 2% in Q4 2023, selling an estimated $33.7K and leaving 7,165 shares worth $1.58M. The position accounts for 0.17% of the portfolio, ranked #141.

Desjardins Global Asset Management first reported a position in UTHR in Q1 2023 and has held it in 3 quarters since. The position peaked at $1.65M in Q3 2023. 535 funds tracked by Wall St. Rank hold UTHR as of Q4 2023.

Desjardins Global Asset Management held 7,165 shares of United Therapeutics worth $1.58M as of Q4 2023.
Desjardins Global Asset Management sold 146 United Therapeutics shares in Q4 2023, an estimated $33.7K.
United Therapeutics made up 0.17% of Desjardins Global Asset Management's portfolio in Q4 2023, its #141 holding.
Desjardins Global Asset Management first reported a position in United Therapeutics in Q1 2023 and has held it in 3 quarters since.
Desjardins Global Asset Management's United Therapeutics position peaked at $1.65M in Q3 2023.
535 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.